ArticleCureus2025
Febuxostat Versus Allopurinol Use in Gout Patients: A Real-World Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesThe primary goal of this study is the epidemiological observation and characterisation of a gout patient cohort. Following this, allopurinol, febuxostat, or no uric acid-lowering treatment was given, and cardiovascular events and deaths during the follow-up were noted. We precisely documented and studied each patient's comorbidities and co-medications for the analysis.
methodOur analysis included 208 gout patients, focusing on their epidemiological and clinical features. We monitored the treatment progress of 155 patients using the prescribed medications. Patients received treatment in the rheumatology department at Dresden University Hospital. On average, participants were followed up for 248.7 weeks (4.8 years). We conducted an association study, grouping participants based on their primary uric acid-lowering medication (if they used it for at least 60% of the follow-up period).
resultsIn the follow-up, 7.5% of patients in the allopurinol group (five patients) and 18.1% (13 patients) in the febuxostat group experienced at least one cardiovascular event. Among participants primarily using allopurinol, four deaths (6%) were recorded, compared to five deaths (6.9%) among those mainly using febuxostat.
conclusionsWhile the febuxostat group showed more events, this was associated with a higher prevalence of almost all risk factors. Interpreting study results and applying them practically remain difficult given the constellation's commonality in clinical life; therefore, careful consideration is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.